Abstract

We aimed to clarify the differences in therapeutic outcomes of patients with pure undifferentiated-type and mixed undifferentiated-type cancers who underwent endoscopic submucosal dissection (ESD), and whether pre-treatment diagnosis of mixed undifferentiated-type cancer is associated with requiring additional surgery after ESD. Patients subjected to ESD as initial treatment between May 2005 and March 2017 were enrolled. There were 277 undifferentiated-type cancers (265 patients). Histologically, 258 lesions were pure-type and 19 were mixed-type. We compared therapeutic outcomes and pre-treatment factors (tumour diameter, tumour depth, ulcerative findings, tumour location, and the macroscopic, and histological type of the biopsy specimen) between pure-type and mixed-type lesions, and between cases not requiring additional surgeries and cases requiring additional surgeries. Tumour diameter >20 mm, submucosal invasion, and the presence of ulcerative findings made pre-treatment diagnosis more difficult for mixed-type than for pure-type lesions. In cases requiring additional surgery, pre-treatment diagnosis of mixed-type lesions was significantly more likely than pre-treatment diagnosis of pure-type lesions. For mixed-type lesions, pre-treatment histological diagnosis and careful consideration are necessary to determine indications for ESD to avoid additional surgery after ESD.

Details

Title
Undifferentiated-type predominant mixed-type early gastric cancer is a significant risk factor for requiring additional surgeries after endoscopic submucosal dissection
Author
Horiuchi Yusuke 1 ; Fujisaki Junko 1 ; Yamamoto Noriko 2 ; Ishizuka Naoki 3 ; Ishiyama Akiyoshi 1 ; Yoshio Toshiyuki 1 ; Hirasawa Toshiaki 1 ; Yamamoto Yorimasa 4 ; Nagahama Masatsugu 4 ; Takahashi, Hiroshi 4 ; Tsuchida Tomohiro 1 

 Cancer Institute Hospital, Department of Gastroenterology, Tokyo, Japan (GRID:grid.486756.e) (ISNI:0000 0004 0443 165X) 
 Cancer Institute Hospital, Department of Pathology, Tokyo, Japan (GRID:grid.486756.e) (ISNI:0000 0004 0443 165X) 
 Cancer Institute Hospital, Department of Clinical Trial Planning and Management, Tokyo, Japan (GRID:grid.486756.e) (ISNI:0000 0004 0443 165X) 
 Showa University Fujigaoka Hospital, Department of Gastroenterology, Kanagawa, Japan (GRID:grid.412808.7) (ISNI:0000 0004 1764 9041) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2393004932
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.